[pubmed] Low-dose rituximab treatment for new-onset generalized myasthenia gravis
Posté : 04 mars 2021 12:00
J Neuroimmunol. 2021 Feb 24;354:577528. doi: 10.1016/j.jneuroim.2021.577528. Online ahead of print.
ABSTRACT
The aim of this retrospective case series study was to evaluate the response and durability of rituximab in patients with new-onset acetylcholine receptor positive (AChR +) generalized myasthenia gravis (MG). Patients were initiated with low-dose rituximab treatment within 3.5 months of onset without concomitant oral immunosuppressants. Seventeen patients (89%) remained relapse-free with a mean follow-up of 51.3 months. Clinical improvement was observed in parallel with the maintenance of low-dose corticosteroids or the complete discontinuation of corticosteroids. Long-term depletion of B cells with low-dose rituximab treatment has shown favorable efficacy and tolerance in reducing disease activity for AChR+ generalized MG.
PMID:33662696 | DOI:10.1016/j.jneuroim.2021.577528
Source: https://pubmed.ncbi.nlm.nih.gov/3366269 ... 1&v=2.14.2